Global leader in Human Challenge vaccine development

Source: MedTech Trends

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Open Orphan Plc

More articles like this

Open Orphan Plc

Considerations on Manufacturing Challenge Agents webinar

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses

Open Orphan Plc

Open Orphan could realise £20 million in first non-core asset IPO

Co-founder Cathal Friel has indicated that a series of spinouts could unlock £750 million for shareholders in the Dublin-based pharma company. Open Orphan, the Dublin-listed pharmaceutical services company run by Cathal Friel, will launch an initial public offering

Open Orphan Plc

Open Orphan considers spinning out assets

Specialist pharmaceutical services clinical research company, Open Orphan, is considering a possible spin-out of certain non-core development intellectual property assets. The company said the potential demerger is at an advanced stage of planning. The assets include HVO-001, a

Open Orphan Plc

Open Orphan plans for possible spin out of non-core assets

Dublin-listed pharmaceutical services company Open Orphan said it is planning for a possible spin-out of some of its non-core development intellectual property assets. The company said it believed the assets in question were best developed separately from the core services

Open Orphan Plc

Open Orphan monetisation of some of non-core assets

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that it is at an advanced stage in planning for a

Open Orphan Plc

Open Orphan’s hVIVO launches its Disease in Motion platform

Open Orphan plc (LON:ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation and world leader in vaccine and antiviral testing using human challenge clinical trials, has announced that hVIVO, a subsidiary of Open Orphan, has officially launched its Disease in